Abstract
A large number of therapeutic roles have been proposed for σ1 receptors but the involvement of σ1 receptor in non-acute pain had not been well explored up to now. σ1 receptor knock-out mice became available offering us the possibility to study the role of σ1 receptor in nociception, particularly in models where central sensitization processes play a significant role. Given the attractive therapeutic potential, we have developed a chemical program aimed at the discovery of novel and selective σ1 ligands. Herein we discuss the rational basis of this approach and report preliminary pharmacological results of several chemical series and aspects of their structure-activity relationship on σ1 receptor. Functional data in pain models are presented mainly on one series that provide evidence to consider selective σ1 receptor antagonists an innovative and alternative approach for treating neuropathic pain.
Keywords: Neuropathic pain, analgesia, sigma-1 antagonists, sigma-1 knock-out, central sensitization
Central Nervous System Agents in Medicinal Chemistry
Title: Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain
Volume: 9 Issue: 3
Author(s): Jose Luis Diaz, Daniel Zamanillo, Jordi Corbera, Jose Manuel Baeyens, Rafael Maldonado, Miquel Angel Pericàs, Jose Miguel Vela and Antoni Torrens
Affiliation:
Keywords: Neuropathic pain, analgesia, sigma-1 antagonists, sigma-1 knock-out, central sensitization
Abstract: A large number of therapeutic roles have been proposed for σ1 receptors but the involvement of σ1 receptor in non-acute pain had not been well explored up to now. σ1 receptor knock-out mice became available offering us the possibility to study the role of σ1 receptor in nociception, particularly in models where central sensitization processes play a significant role. Given the attractive therapeutic potential, we have developed a chemical program aimed at the discovery of novel and selective σ1 ligands. Herein we discuss the rational basis of this approach and report preliminary pharmacological results of several chemical series and aspects of their structure-activity relationship on σ1 receptor. Functional data in pain models are presented mainly on one series that provide evidence to consider selective σ1 receptor antagonists an innovative and alternative approach for treating neuropathic pain.
Export Options
About this article
Cite this article as:
Diaz Luis Jose, Zamanillo Daniel, Corbera Jordi, Baeyens Manuel Jose, Maldonado Rafael, Pericàs Angel Miquel, Vela Miguel Jose and Torrens Antoni, Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871524910909030172
DOI https://dx.doi.org/10.2174/1871524910909030172 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioinformatics Analysis of Functional Relations Between CNPs Regions
Current Bioinformatics Metabolic Basis of Sporadic Alzeimer’s Disease. Role of Hormones Related to Energy Metabolism
Current Pharmaceutical Design A Review of Inadequate and Excessive Weight Gain in Pregnancy
Current Women`s Health Reviews Pharmacogenetic Variation in Drug Oxidizing CYPs: Impact on Drug Therapy, Drug Safety and Drug Interactions
Current Pharmacogenomics The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Recent Patents on Inflammation & Allergy Drug Discovery Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy Therapy of No-Type I Bipolar Spectrum Disorders: A Systematic Review
Current Psychiatry Reviews Molecular Interactions of Different Steroids Contributing to Sebum Production. Review
Current Drug Targets Diagnosis and Treatment of Common Sleep Disorders in Adolescence
Adolescent Psychiatry Moraceae Plants with Tyrosinase Inhibitory Activity: A Review
Mini-Reviews in Medicinal Chemistry NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy
Current Gene Therapy Paracrine Provision of Lipids in the Immune System
Current Immunology Reviews (Discontinued) γ-Secretase, Apolipoprotein E and Cellular Cholesterol Metabolism
Current Alzheimer Research Inhibitors of Catechol-O-Methyltransferase
CNS & Neurological Disorders - Drug Targets Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Current Pharmaceutical Design Assessing Depression in Patients with an Acute Coronary Syndrome: A Literature Review
Current Psychiatry Reviews Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression
Current Psychiatry Reviews Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) Complexity in Protein Folding: Simulation Meets Experiment
Current Physical Chemistry Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca
Current Drug Abuse Reviews